LTX-109

DB12711InvestigationalSmall molecule

LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.

Mechanism: Pharmacologically active on Cytoplasmic membrane
Curator reviewed
Formula / weight: C₄₃H₆₉N₁₁O₃ · 788.099 g/mol (avg)
Code names: LTX-109

Resolves to

Compound

Structure

CC(C)(C)C1=C(C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCC2=CC=CC=C2)C2=C(N1)C(=CC(=C2)C(C)(C)C)C(C)(C)C

What you can answer from here — as of July 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of LTX-109, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.